A Pfizer win could cost taxpayers billions of dollars and erase an important control on pharma marketing.

Pharma companies may see campaign largesse as leverage if Biden follows through on promises to address high drug prices.

In a year when multiple health systems have come under fire for suing patients, the AHA has made no concrete move to develop an industry standard.

Of all the ways drug companies try to protect sales as patents expire, authorized generics are by far the most profitable,

Executives expressed support for eliminating drug rebates, increasing price transparency and shifting to a more value-based pricing system.

An end to drug rebates would produce uncertain ricochets, including higher premiums for consumers, that would produce new winners and losers.

New research is turning up evidence of rebates distorting the market, often leaving effective, less expensive generics off of formularies.

Companies have slowed enrollment in high-deductible health coverage as a strong job market gives workers bargaining power over pay and benefits.